Association between serum soluble Toll‑like receptor 2 and 4 and the risk of breast cancer

El‑Kharashy,Ghada; Gowily,Ahmed; Okda,Tarek; Houssen,Maha

doi:10.3892/mco.2020.2200

Association between serum soluble Toll‑like receptor 2 and 4 and the risk of breast cancer

Authors:
- Ghada El‑Kharashy
- Ahmed Gowily
- Tarek Okda
- Maha Houssen
View Affiliations

Affiliations: Department of Biochemistry, Faculty of Pharmacy, Damanhour University, Damanhour 22511, Egypt, Department of Oncology Medicine, Faculty of Medicine, Alexandria University, Alexandria 21111, Egypt
Published online on: December 24, 2020 https://doi.org/10.3892/mco.2020.2200
Article Number: 38
Copyright: © El‑Kharashy et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Soluble Toll‑like receptor (sTLR) 2 and 4 are endogenous negative regulators of TLR2 and TLR4 signaling. Therefore, the present study aimed to determine the serum levels of sTLR2 and 4, and to investigate the association between their levels and the clinicopathological parameters of patients with breast cancer. A total of 100 female patients with breast cancer (50 non‑metastatic and 50 metastatic), as well as 50 healthy control volunteers were enrolled in the present study, and serum levels of sTLR2 and 4 were determined by ELISA. A significant increase in serum sTLR2 was detected in patients with non‑metastatic (2,258.2±1,832.44 pg/ml) and metastatic (5,997.4±8,585.23 pg/ml) breast cancer, compared with the control group (1,106.8± 99.93 pg/ml; P=0.0001). A significant increase in serum sTLR4 was also detected in patients with both non‑metastatic (1,945.2±1,709.53 pg/ml) and metastatic breast cancer (7,800.1±13,041.28 pg/ml), compared with the control group (1,106.8±108.32 pg/ml; P=0.0001). Furthermore, a positive correlation was observed between the levels of serum sTLR4 and 2 and clinicopathological parameters, such as progesterone receptor and estrogen receptor expression. In conclusion, sTLR2 and sTLR4 may be potential biomarkers of breast cancer susceptibility.

View Figures

View References

1	Nur Husna SM, Tan HT, Mohamud R, Dyhl-Polk A and Wong KK: Inhibitors targeting CDK4/6, PARP and PI3K in breast cancer. A review. Ther Adv Med Oncol. 10(1758835918808509)2018.PubMed/NCBI View Article : Google Scholar
2	Dubey AK, Gupta U and Jain S: Breast cancer statistics and prediction methodology: A systematic review and analysis. Asian Pacific J Cancer Prev. 16:4237–4245. 2015.PubMed/NCBI View Article : Google Scholar
3	Ayala-Cuellar AP, Cho J and Choi KC: Toll-like receptors: A pathway alluding to cancer control. J Cell Physiol. 234:21707–21715. 2019.PubMed/NCBI View Article : Google Scholar
4	McGettrick AF and O'Neill LA: Localisation and trafficking of Toll-like receptors: An important mode of regulation. Curr Opin Immunol. 22:20–27. 2010.PubMed/NCBI View Article : Google Scholar
5	Kawai T and Akira S: The role of pattern-recognition receptors in innate immunity: Update on Toll-like receptors. Nat Immunol. 11:373–384. 2010.PubMed/NCBI View Article : Google Scholar
6	Ahmed A, Wang JH and Redmond HP: Silencing of TLR4 increases tumor progression and lung metastasis in a murine model of breast cancer. Ann Surg Oncol. 20 (Suppl 3):S389–S396. 2013.PubMed/NCBI View Article : Google Scholar
7	Grimmig T, Moench R, Kreckel J, Haack S, Rueckert F, Rehder R, Tripathi S, Ribas C, Chandraker A, Germer CT, et al: Toll like receptor 2, 4, and 9 signaling promotes autoregulative tumor cell growth and VEGF/PDGF expression in human pancreatic cancer. Int J Mol Sci. 17(2060)2016.PubMed/NCBI View Article : Google Scholar
8	Al-Harras MF, Houssen ME, Shaker ME, Farag K, Farouk O, Monir R, El-Mahdy R and Abo-Hashem EM: Polymorphisms of glutathione S-transferase π 1 and toll-like receptors 2 and 9: Association with breast cancer susceptibility. Oncol Lett. 11:2182–2188. 2016.PubMed/NCBI View Article : Google Scholar
9	Houssen ME, El-Mahdy RH and Shahin DA: Serum soluble toll-like receptor 2: A novel biomarker for systemic lupus erythematosus disease activity and lupus-related cardiovascular dysfunction. Int J Rheum Dis. 19:685–692. 2016.PubMed/NCBI View Article : Google Scholar
10	Dulay AT, Buhimschi CS, Zhao G, Oliver EA, Mbele A, Jing S and Buhimschi IA: Soluble TLR2 is present in human amniotic fluid and modulates the intraamniotic inflammatory response to infection. J Immunol. 182:7244–7253. 2009.PubMed/NCBI View Article : Google Scholar
11	Henrick BM, Yao XD, Taha AY, German JB and Rosenthal KL: Insights into soluble Toll-like receptor 2 as a downregulator of virally induced inflammation. Front Immunol. 7(291)2016.PubMed/NCBI View Article : Google Scholar
12	Langjahr P, Díaz-Jiménez D, De la Fuente M, Rubio E, Golenbock D, Bronfman FC, Quera R, González MJ and Hermoso MA: Metalloproteinase-dependent TLR2 ectodomain shedding is involved in soluble toll-like receptor 2 (sTLR2) production. PLoS One. 9(e104624)2014.PubMed/NCBI View Article : Google Scholar
13	Ten Oever J, Kox M, van de Veerdonk FL, Mothapo KM, Slavcovici A, Jansen TL, Tweehuysen L, Giamarellos-Bourboulis EJ, Schneeberger PM, Wever PC, et al: The discriminative capacity of soluble Toll-like receptor (sTLR)2 and sTLR4 in inflammatory diseases. BMC Immunol. 15(55)2014.PubMed/NCBI View Article : Google Scholar
14	Domenis R, Cifù A, Marinò D, Fabris M, Niazi KR, Soon-Shiong P and Curcio F: Toll-like receptor-4 activation boosts the immunosuppressive properties of tumor cells-derived exosomes. Sci Rep. 9(8457)2019.PubMed/NCBI View Article : Google Scholar
15	Bhattacharya D and Yusuf N: Expression of toll-like receptors on breast tumors: Taking a toll on tumor microenvironment. Int J Breast Cancer. 2012(716564)2012.PubMed/NCBI View Article : Google Scholar
16	Yang CX, Li CY and Feng W: Toll-like receptor 4 genetic variants and prognosis of breast cancer. Tissue Antigens. 81:221–226. 2013.PubMed/NCBI View Article : Google Scholar
17	Yusuf N: Toll-like receptors and breast cancer. Front Immunol. 5(84)2014.
18	Hossain MJ, Morandi E, Tanasescu R, Frakich N, Caldano M, Onion D, Faraj TA, Erridge C and Gran B: The soluble form of toll-like receptor 2 is elevated in serum of multiple sclerosis patients: A novel potential disease biomarker. Front Immunol. 9(457)2018.PubMed/NCBI View Article : Google Scholar
19	Holst B, Szakmany T, Raby AC, Hamlyn V, Durno K, Hall JE and Labéta MO: Soluble Toll-like receptor 2 is a biomarker for sepsis in critically ill patients with multi-organ failure within 12 h of ICU admission. Intensive Care Med Exp. 5(2)2017.PubMed/NCBI View Article : Google Scholar
20	Liew FY, Xu D, Brint EK and O'Neill LA: Negative regulation of toll-like receptor-mediated immune responses. Nat Rev Immunol. 5:446–458. 2005.PubMed/NCBI View Article : Google Scholar
21	Wei F, Yang F, Li J, Zheng Y, Yu W, Yang L and Ren X: Soluble Toll-like receptor 4 is a potential serum biomarker in non-small cell lung cancer. Oncotarget. 7:40106–40114. 2016.PubMed/NCBI View Article : Google Scholar
22	Huang B, Zhao J, Unkeless JC, Feng ZH and Xiong H: TLR signaling by tumor and immune cells: A double-edged sword. Oncogene. 27:218–224. 2008.PubMed/NCBI View Article : Google Scholar
23	Huang B, Zhao J, Li H, He KL, Chen Y, Chen SH, Mayer L, Unkeless JC and Xiong H: Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res. 65:5009–5014. 2005.PubMed/NCBI View Article : Google Scholar